TOKYO -- Japanese drugmaker Shionogi on Friday filed for emergency use approval for its COVID pill, paving the way for Japan's first domestically developed oral COVID treatment.
The drug, code-named S-217622, prevents the coronavirus from replicating in infected cells by inhibiting its protease, an enzyme for protein production. The drug has been in the clinical trial stage since July.
re.jpg?width=178&fit=cover&gravity=faces&dpr=2&quality=medium&source=nar-cms&format=auto&height=100)
